Induction chemotherapy;
Head and neck cancer;
Concurrent radiochemotherapy;
Organ preservation;
SQUAMOUS-CELL CARCINOMA;
LOCALLY ADVANCED HEAD;
INDUCTION CHEMOTHERAPY;
PHASE-III;
CONCOMITANT CHEMORADIOTHERAPY;
LOCOREGIONAL CONTROL;
UNRESECTABLE HEAD;
ADVANCED LARYNX;
CISPLATIN;
SURVIVAL;
D O I:
10.1016/j.ctrv.2015.02.002
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The treatment of patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) is still evolving into the perfect combination of the different multidisciplinary approaches. Induction chemotherapy (ICT) prior to planned definitive local therapy is widely used in this patient population for over 30 years but it is still unclear how to incorporate ICT into multimodality treatment the best. It appears to have a role in selected clinical situations especially for those patients with high risk for distant metastasis. However, since ICT protocols in different studies varies a lot, a comparative and consistent statement of benefits is difficult. We show the recent developments including randomized trials comparing radiochemotherapy (RCT) and ICT followed by definitive RCT here. This review summarizes how la has developed over the years, provides critical remarks of recent developments, and discusses how clinical trials including ICT should be conducted in the future. (C) 2015 Elsevier Ltd. All rights reserved.